Could immunotherapy spare some colon cancer patients from surgery?
NCT ID NCT07409844
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests giving an immunotherapy drug (pembrolizumab) before surgery to people with a specific type of colon cancer (dMMR). The goal is to see if the drug can shrink or eliminate the tumor so some patients may avoid surgery and instead be closely monitored. About 152 adults with stage I to III dMMR colon cancer will join this phase 2 trial across 13 hospitals in Denmark.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER STAGE I are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zealand University Hospital
Køge, 4600, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an AI coach and simple exercises help cancer patients fight frailty?
- Triple therapy takes on rare, aggressive kidney cancer
- Bladder cancer drug delivered directly: a new hope for BCG failures
- Blood test may let cancer patients take safe breaks from immunotherapy
- Immunotherapy combo may boost rectal cancer treatment
- New cocktail aims to make immunotherapy work for common colorectal cancer